Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.76 |
| ▸ | RAB9A | P51151 | 3/20 | 0.76 |
| ▸ | NPC1 | O15118 | 2/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.76 |
| ▸ | ATM | Q13315 | 1/20 | 0.76 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30019714 | 1.00 | MAPT (0.76) | MAPTRAB9ANPC1SMN1; SMN2ATM | |
| SCHEMBL197523 | 0.87 | MAPT (1.00) | MAPTRAB9ANPC1SMN1; SMN2ATM | |
| SCHEMBL15886672 | 0.83 | RAB9A (0.85) | MAPTRAB9ANPC1SMN1; SMN2ATM | |
| SCHEMBL22621614 | 0.79 | MAPT (0.71) | MAPTRAB9ANPC1SMN1; SMN2ATM | |
| SCHEMBL22135838 | 0.79 | MAPT (0.71) | MAPTRAB9ANPC1SMN1; SMN2ATM | |
| SCHEMBL24934039 | 0.79 | MAPT (0.76) | MAPTRAB9ANPC1SMN1; SMN2ATM | |
| SCHEMBL13662727 | 0.79 | MAPT (0.76) | MAPTRAB9ANPC1SMN1; SMN2ATM | |
| SCHEMBL26061296 | 0.76 | MAPT (0.71) | MAPTRAB9ANPC1SMN1; SMN2ATM | |
| SCHEMBL22033516 | 0.75 | MAPT (0.59) | MAPTRAB9ANPC1SMN1; SMN2ATM | |
| SCHEMBL20390878 | 0.75 | MAPT (0.69) | MAPTRAB9ANPC1SMN1; SMN2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3898646-B1 | 3.ALPHA.-HYDROXY-17.BETA.-AMIDE NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF | SAGE THERAPEUTICS LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2023072301-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE COMPOUND AND MEDICAL USE THEREOF | 正大天晴药业集团股份有限公司 | 2023-05-04 | — | — | WO | disclosed |
| US-20120309970-A1 | PLATINUM COMPLEX COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE | UDC IRELAND LTD. (IE) | 2012-12-06 | — | — | US | disclosed |
| US-8247091-B2 | Platinum complex compound and organic electroluminescent device | FUJIFILM CORPORATION (JP) | 2012-08-21 | — | — | US | disclosed |
| US-20110234090-A1 | PLATINUM COMPLEX COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE | FUJIFILM CORPORATION (JP) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309970-A1 | PLATINUM COMPLEX COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE | L1CAM, LIG1, ZC3HAV1L | MAPT 1900/4885RAB9A 1622/4885NPC1 3900/4885 |
| US-20110234090-A1 | PLATINUM COMPLEX COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE | L1CAM, LIG1, ZC3HAV1L | MAPT 1900/4885RAB9A 1622/4885NPC1 3900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.